Refine
Year of publication
Language
- English (45)
- German (2)
- Portuguese (1)
Has Fulltext
- yes (48)
Is part of the Bibliography
- no (48)
Keywords
- Head and neck cancer (3)
- Radiotherapy (3)
- Biomarker (2)
- Breast cancer (2)
- Fasting (2)
- Glioblastoma (2)
- Glucose (2)
- HNSCC (2)
- Ketogenic diet (2)
- Leptin (2)
- Postoperative radiochemotherapy (2)
- Radiation (2)
- Rectal cancer (2)
- composite structures (2)
- head and neck squamous cell carcinoma (2)
- ACLF (1)
- ALL (1)
- AML (1)
- Acute myeloid leukemia (1)
- Addison’s disease (1)
- All-trans retinoic acid (1)
- Alveolar macrophages (1)
- Anakinra (1)
- Antiretroviral therapy (1)
- Antisemitismus (1)
- Back pain (1)
- Bevacizumab (1)
- Bladder cancer (1)
- Bone metastases (1)
- Brasilien (1)
- Business strategy in drug development (1)
- COVID (1)
- CUP (1)
- CXCR4 (1)
- Cancer of unknown primary (1)
- Capecitabine (1)
- Cardiac output (1)
- Caro, Herbert Moritz (1)
- Central nervous system metastases (1)
- Cervical (1)
- Checkpoint inhibitor (1)
- Chemical company (1)
- Chemoradiotherapy (1)
- Cross-sectional study (1)
- Culture positive (1)
- DKTK-ROG (1)
- De-isolation (1)
- Diagnostic differentiation (1)
- Disabling back pain (1)
- Drug therapy (1)
- Echocardiography (1)
- Exil (1)
- Fibroblast (1)
- First site of metastatic disease (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- Genetics research (1)
- Germany (1)
- Guided waves (1)
- Guidelines (1)
- HIV (1)
- HPV (1)
- Hemodynamic management (1)
- Hsp70 (1)
- IHC (1)
- Immunotherapy (1)
- Influenza (1)
- Interleukin-1 (1)
- Jude (1)
- Liposomes (1)
- Locally advanced (1)
- Loco-regional control (1)
- Lymph node (1)
- MLL (1)
- MRI (1)
- Machine learning (1)
- Multinomial logistic regression (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- NAFL (1)
- NASH (1)
- NK cells (1)
- Nanomedicine (1)
- Nek1 (1)
- Nivolumab (1)
- Noninferiority (1)
- Nontuberculous mycobacteria (1)
- Nucleophosmin-1 (1)
- Occupational medicine (1)
- Open pulmonary tuberculosis (1)
- Opportunistic infections (1)
- Oxaliplatin (1)
- PD-1 inhibitor (1)
- Parainfluenza (1)
- Patterns of care (1)
- Pneumonia (1)
- Predictive markers (1)
- Preoperative radiochemotherapy (1)
- Prevalence (1)
- Prevention (1)
- Prognostic (1)
- Protease inhibitor therapy (1)
- Pulse contour analysis (1)
- Pulse pressure variation (1)
- Radical cystectomy (1)
- Radiomics (1)
- Renal lesions (1)
- Respiratory infections (1)
- Respiratory syncytial virus (1)
- SCCHN (1)
- SDF-1 (1)
- SPSS (1)
- Salivary gland carcinoma (1)
- Sputum smear-negative (1)
- Stroke volume variation (1)
- Superinfection (1)
- Surgery (1)
- Surgical oncology (1)
- TB-therapy (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- Targeted drug delivery (1)
- Thermodilution (1)
- Transitional cell carcinoma (1)
- Treatment protocol (1)
- Tuberculosis (1)
- Upper respiratory tract infection (1)
- Urothelial cancer (1)
- Validation (1)
- accident (1)
- acute decompensation (1)
- acute leukemia (1)
- acute-on-chronic liver failure (1)
- adrenal insuffciency (1)
- adult (1)
- basal cell carcinoma (1)
- bevacizumab (1)
- cerebral radiation necrosis (1)
- cerebrospinal fluid (1)
- cervical cancer (1)
- chemotherapy (1)
- chromosomal translocations (1)
- cirrhosis (1)
- clinical trial (1)
- colorectal cancer (1)
- computed tomography (1)
- diffusion-weighted magnetic resonance imaging (1)
- discontinuous dose dependency (1)
- dysbiosis (1)
- fractionation (1)
- gene signature (1)
- hedgehog signaling pathway (1)
- hepatic encephalopathy (1)
- image-based risk modelling (1)
- immune modulation (1)
- inflammation (1)
- injury (1)
- liver (1)
- lockdown (1)
- low-dose radiation therapy (1)
- machine learning (1)
- magnetic resonance imaging (1)
- medulloblastoma (1)
- microbiome (1)
- multiplexed immunofluorescence (1)
- neoadjuvant chemoradiotherapy (1)
- omega stringer (1)
- open guided waves (1)
- oral cavity cancer (1)
- p16 (1)
- p53 (1)
- pediatric intensive care (1)
- personalised therapy (1)
- phase I (1)
- portal hypertension (1)
- portosystemic shunt (1)
- postoperative radiochemotherapy (1)
- postoperative radiotherapy (1)
- predictive biomarker (1)
- prognostic biomarker (1)
- prognostic marker (1)
- propensity score matching (1)
- radiation oncology (1)
- radiomic (1)
- radiosensitization (1)
- radiotherapy (1)
- radiotherapy resistance (1)
- randomized (1)
- reference damage (1)
- retrospective trial (1)
- scanning laser Doppler vibrometry (1)
- signal processing (1)
- spontaneous portosystemic shunt (1)
- structural health monitoring (1)
- subgrouping (1)
- targeted therapy (1)
- translocation partner genes (1)
- trauma (1)
- vismodegib (GDC-0449) (1)
- xenograft (1)
- Übersetzer (1)
Institute
- Medizin (39)
- Physik (3)
- Biochemie und Chemie (1)
- Biowissenschaften (1)
- Georg-Speyer-Haus (1)
- Informatik (1)
- Mathematik (1)
- Universitätsbibliothek (1)
The third dataset dedicated to the Open Guided Waves platform aims at carbon fiber composite plates with an additional omega stringer at constant temperature conditions. The two structures used in this work are representative for real aircraft components. Comprehensive measurements were recorded in order to study (I) the impact of the omega stringer on guided wave propagation, and (II) elliptical reference damages of different sizes located at three separate positions on the structure. Measurements were recorded for narrowband excitation (5-cycle toneburst with varying carrier frequencies) and broadband excitation (using chirp waveforms). The paper presents the results of a technical validation including numerical modelling, and enables further research, for example related to probability of detection (POD) analysis.
Ultrasonic guided waves have been used successfully in structural health monitoring systems to detect damage in isotropic and composite materials with simple and complex geometry. A limitation of current research is given by a lack of freely available benchmark measurements to comparatively evaluate existing methods. This article introduces the extendable online platform Open Guided Waves (http://www.open-guided-waves.de) where high-quality and well-documented datasets for guided wave-based inspections are provided. In this article, we describe quasi-isotropic carbon-fiber-reinforced polymer plates with embedded piezoelectric transducers as a first benchmark structure. Intentionally, this is a structure of medium complexity to enable many researchers to apply their methods. In a first step, ultrasound and X-ray measurements were acquired to verify pristine conditions. Next, mechanical testing was done to determine the stiffness tensor and sample density based on standard test procedures. Guided wave measurements were divided into two parts: first, acoustic wave fields were acquired for a broad range of frequencies by three-dimensional scanning laser Doppler vibrometry. Second, structural health monitoring measurements in the carbon-fiber-reinforced polymer plate were collected at constant temperature using a distributed transducer network and a surface-mounted reversible defect model. Initial results serving as validation are presented and discussed.
Background & Aims: Spontaneous portosystemic shunts (SPSS) frequently develop in liver cirrhosis. Recent data suggested that the presence of a single large SPSS is associated with complications, especially overt hepatic encephalopathy (oHE). However, the presence of >1 SPSS is common. This study evaluates the impact of total cross-sectional SPSS area (TSA) on outcomes in patients with liver cirrhosis.
Methods: In this retrospective international multicentric study, CT scans of 908 cirrhotic patients with SPSS were evaluated for TSA. Clinical and laboratory data were recorded. Each detected SPSS radius was measured and TSA calculated. One-year survival was the primary endpoint and acute decompensation (oHE, variceal bleeding, ascites) was the secondary endpoint.
Results: A total of 301 patients (169 male) were included in the training cohort. Thirty percent of all patients presented with >1 SPSS. A TSA cut-off of 83 mm2 was used to classify patients with small or large TSA (S-/L-TSA). Patients with L-TSA presented with higher model for end-stage liver disease score (11 vs. 14) and more commonly had a history of oHE (12% vs. 21%, p <0.05). During follow-up, patients with L-TSA experienced more oHE episodes (33% vs. 47%, p <0.05) and had lower 1-year survival than those with S-TSA (84% vs. 69%, p <0.001). Multivariate analysis identified L-TSA (hazard ratio 1.66; 95% CI 1.02–2.70, p <0.05) as an independent predictor of mortality. An independent multicentric validation cohort of 607 patients confirmed that patients with L-TSA had lower 1-year survival (77% vs. 64%, p <0.001) and more oHE development (35% vs. 49%, p <0.001) than those with S-TSA.
Conclusion: This study suggests that TSA >83 mm2 increases the risk for oHE and mortality in patients with cirrhosis. Our results support the clinical use of TSA/SPSS for risk stratification and decision-making in the management of patients with cirrhosis.
Lay summary: The prevalence of spontaneous portosystemic shunts (SPSS) is higher in patients with more advanced chronic liver disease. The presence of more than 1 SPSS is common in advanced chronic liver disease and is associated with the development of hepatic encephalopathy. This study shows that total cross-sectional SPSS area (rather than diameter of the single largest SPSS) predicts survival in patients with advanced chronic liver disease. Our results support the clinical use of total cross-sectional SPSS area for risk stratification and decision-making in the management of SPSS.
Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize the chromosomal rearrangement of individual acute leukemia patients. We present data of the molecular characterization of 1590 MLL-rearranged biopsy samples obtained from acute leukemia patients. The precise localization of genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and novel TPGs identified. All patients were classified according to their gender (852 females and 745 males), age at diagnosis (558 infant, 416 pediatric and 616 adult leukemia patients) and other clinical criteria. Combined data of our study and recently published data revealed a total of 121 different MLL rearrangements, of which 79 TPGs are now characterized at the molecular level. However, only seven rearrangements seem to be predominantly associated with illegitimate recombinations of the MLL gene (~ 90%): AFF1/AF4, MLLT3/AF9, MLLT1/ENL, MLLT10/AF10, ELL, partial tandem duplications (MLL PTDs) and MLLT4/AF6, respectively. The MLL breakpoint distributions for all clinical relevant subtypes (gender, disease type, age at diagnosis, reciprocal, complex and therapy-induced translocations) are presented. Finally, we present the extending network of reciprocal MLL fusions deriving from complex rearrangements.
Comprehensive analysis of tumour sub-volumes for radiomic risk modelling in locally advanced HNSCC
(2020)
Simple Summary: Radiomic risk models are usually based on imaging features, which are extracted from the entire gross tumour volume (GTV entire ). This approach does not explicitly consider the complex biological structure of the tumours. Therefore, in this retrospective study, we investigated the prognostic value of radiomic analyses based on different tumour sub-volumes using computed tomography imaging of patients with locally advanced head and neck squamous cell carcinoma who were treated with primary radio-chemotherapy. The GTV entire was cropped by different margins to define the rim and corresponding core sub-volumes of the tumour. Furthermore, the best performing tumour rim sub-volume was extended into surrounding tissue with different margins. As a result, the models based on the 5 mm tumour rim and on the 3 mm extended rim sub-volume showed an improved performance compared to models based on the corresponding tumour core. This indicates that the consideration of tumour sub-volumes may help to improve radiomic risk models.
Abstract: Imaging features for radiomic analyses are commonly calculated from the entire gross tumour volume (GTVentire). However, tumours are biologically complex and the consideration of different tumour regions in radiomic models may lead to an improved outcome prediction. Therefore, we investigated the prognostic value of radiomic analyses based on different tumour sub-volumes using computed tomography imaging of patients with locally advanced head and neck squamous cell carcinoma. The GTVentire was cropped by different margins to define the rim and the corresponding core sub-volumes of the tumour. Subsequently, the best performing tumour rim sub-volume was extended into surrounding tissue with different margins. Radiomic risk models were developed and validated using a retrospective cohort consisting of 291 patients in one of the six Partner Sites of the German Cancer Consortium Radiation Oncology Group treated between 2005 and 2013. The validation concordance index (C-index) averaged over all applied learning algorithms and feature selection methods using the GTVentire achieved a moderate prognostic performance for loco-regional tumour control (C-index: 0.61 ± 0.04 (mean ± std)). The models based on the 5 mm tumour rim and on the 3 mm extended rim sub-volume showed higher median performances (C-index: 0.65 ± 0.02 and 0.64 ± 0.05, respectively), while models based on the corresponding tumour core volumes performed less (C-index: 0.59 ± 0.01). The difference in C-index between the 5 mm tumour rim and the corresponding core volume showed a statistical trend (p = 0.10). After additional prospective validation, the consideration of tumour sub-volumes may be a promising way to improve prognostic radiomic risk models.
Purpose: To develop and validate a CT-based radiomics signature for the prognosis of loco-regional tumour control (LRC) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated by primary radiochemotherapy (RCTx) based on retrospective data from 6 partner sites of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG).
Material and methods: Pre-treatment CT images of 318 patients with locally advanced HNSCC were collected. Four-hundred forty-six features were extracted from each primary tumour volume and then filtered through stability analysis and clustering. First, a baseline signature was developed from demographic and tumour-associated clinical parameters. This signature was then supplemented by CT imaging features. A final signature was derived using repeated 3-fold cross-validation on the discovery cohort. Performance in external validation was assessed by the concordance index (C-Index). Furthermore, calibration and patient stratification in groups with low and high risk for loco-regional recurrence were analysed.
Results: For the clinical baseline signature, only the primary tumour volume was selected. The final signature combined the tumour volume with two independent radiomics features. It achieved moderately good discriminatory performance (C-Index [95% confidence interval]: 0.66 [0.55–0.75]) on the validation cohort along with significant patient stratification (p = 0.005) and good calibration.
Conclusion: We identified and validated a clinical-radiomics signature for LRC of locally advanced HNSCC using a multi-centric retrospective dataset. Prospective validation will be performed on the primary cohort of the HNprädBio trial of the DKTK-ROG once follow-up is completed.
Medulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy. Treatment toxicity is high and produces disabling long-term side effects. The sonic hedgehog (SHH) subgroup is highly overrepresented in the post-pubertal and adult population and can be targeted by smoothened (SMO) inhibitors. No practice-changing prospective randomized data have been generated in adults. The EORTC 1634-BTG/NOA-23 trial will randomize patients between standard-dose vs. reduced-dosed craniospinal radiotherapy and SHH-subgroup patients between the SMO inhibitor sonidegib (OdomzoTM, Sun Pharmaceuticals Industries, Inc., New York, USA) in addition to standard radio-chemotherapy vs. standard radio-chemotherapy alone to improve outcomes in view of decreased radiotherapy-related toxicity and increased efficacy. We will further investigate tumor tissue, blood, and cerebrospinal fluid as well as magnetic resonance imaging and radiotherapy plans to generate information that helps to further improve treatment outcomes. Given that treatment side effects typically occur late, long-term follow-up will monitor classic side effects of therapy, but also health-related quality of life, cognition, social and professional outcome, and reproduction and fertility. In summary, we will generate unprecedented data that will be translated into treatment changes in post-pubertal patients with medulloblastoma and will help to design future clinical trials.
(1) Background: Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who are biologically at high risk for the development of loco–regional recurrences after postoperative radiotherapy (PORT) but at intermediate risk according to clinical risk factors may benefit from additional concurrent chemotherapy. In this matched-pair study, we aimed to identify a corresponding predictive gene signature. (2) Methods: Gene expression analysis was performed on a multicenter retrospective cohort of 221 patients that were treated with postoperative radiochemotherapy (PORT-C) and 283 patients who were treated with PORT alone. Propensity score analysis was used to identify matched patient pairs from both cohorts. From differential gene expression analysis and Cox regression, a predictive gene signature was identified. (3) Results: 108 matched patient pairs were selected. We identified a 2-metagene signature that stratified patients into risk groups in both cohorts. The comparison of the high-risk patients between the two types of treatment showed higher loco–regional control (LRC) after treatment with PORT-C (p < 0.001), which was confirmed by a significant interaction term in Cox regression (p = 0.027), i.e., the 2-metagene signature was indicative for the type of treatment. (4) Conclusion: We have identified a novel gene signature that may be helpful to identify patients with high-risk HNSCC amongst those at intermediate clinical risk treated with PORT, who may benefit from additional concurrent chemotherapy.